Kane Biotech (TSE:KNE) has released an update.
Kane Biotech marks a significant milestone with its first commercial sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global, following U.S. FDA 510(k) clearance and an exclusive distribution agreement. The company also solidified its production capabilities through a long-term manufacturing deal with Halo Pharma, ensuring full-scale production to meet the burgeoning market demand. These developments signify Kane Biotech’s growing presence in the advanced wound care sector, with positive feedback from initial product trials.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.
